Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total value of $732,750.00. Following the completion of the transaction, the chief executive officer now owns 1,309,487 shares of the company’s stock, valued at $63,968,439.95. The trade was a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.58, for a total value of $698,700.00.
• On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.

Apogee Therapeutics Price Performance

NASDAQ:APGE traded down $8.16 during mid-day trading on Friday, reaching $41.05. The stock had a trading volume of 1,366,016 shares, compared to its average volume of 509,403. The stock has a 50-day simple moving average of $48.70 and a two-hundred day simple moving average of $48.90. The stock has a market capitalization of $1.85 billion, a PE ratio of -16.96 and a beta of 2.26. Apogee Therapeutics, Inc. has a 12 month low of $30.84 and a 12 month high of $72.29.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Finally, Wedbush raised their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.71.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Apogee Therapeutics in the second quarter valued at approximately $660,000. Point72 Asset Management L.P. grew its stake in shares of Apogee Therapeutics by 162.7% during the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after buying an additional 438,036 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Apogee Therapeutics during the second quarter worth $706,000. Victory Capital Management Inc. grew its stake in shares of Apogee Therapeutics by 56.8% during the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock worth $6,149,000 after buying an additional 56,607 shares during the last quarter. Finally, Waypoint Capital Advisors LLC bought a new stake in shares of Apogee Therapeutics during the third quarter worth $36,835,000. 79.04% of the stock is owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.